Genzyme to Sell Third Wave s Colorectal Cancer PGx Test in North America | GenomeWeb

NEW YORK, Oct. 27 (GenomeWeb News) - Genzyme Genetics will sell Third Wave's Invader UGT1A1 molecular assay to identify colorectal cancer patients who could be considered for, or currently undergoing, chemotherapy with Camptosar, the companies said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.